https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=SERES_THERAPEUTICSSERES THERAPEUTICS - Revizia istoricului2026-04-05T12:31:31ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=SERES_THERAPEUTICS&diff=429775&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei SERES THERAPEUTICS listata cu simbolul US.MCRB ==Descriere companie== Seres Therapeutics,(http://serestherapeutics.com/) Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome...2024-09-18T18:11:41Z<p>Pagină nouă: Pagina dedicata companiei SERES THERAPEUTICS listata cu simbolul US.MCRB ==Descriere companie== Seres Therapeutics,(http://serestherapeutics.com/) Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei SERES THERAPEUTICS listata cu simbolul US.MCRB<br />
<br />
==Descriere companie==<br />
Seres Therapeutics,(http://serestherapeutics.com/) Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.MCRB" /><br />
<br />
==Ultimele stiri despre SERES THERAPEUTICS (US.MCRB)==<br />
<dynamicpagelist><br />
category=US.MCRB<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.MCRB]][[Categorie:Stiri despre companii]]</div>Admin